NGNE · Neurogene Inc. Common Stock
View on chartInsiders & Stakes
| Samsara BioCapital GP, LLC 10% Owner | ▲ Buy | Open Market | 1,717,127 Shares held | 11/26/2024 | View profile |
| BAKER BROS. ADVISORS LP Director | ▼ Sell | Other | 1,658,190 Shares held | 10/5/2023 | View profile |
| McMinn Rachel Chief Executive Officer | ▲ Buy | Option Exercise | 1,345,063 Shares held | 9/22/2026 | View profile |
| Cvijic Christine Mikail President and CFO | ▼ Sell | Open Market | 84,040 Shares held | 7/7/2026 | View profile |
| Patel Priti Chief Medical Officer | ▼ Sell | Open Market | 37,313 Shares held | 4/3/2023 | View profile |
| Cobb Stuart Chief Scientific Officer | ▼ Sell | Open Market | 30,497 Shares held | 3/13/2026 | View profile |
| DRACHMAN JONATHAN G President and CEO | ▲ Buy | Open Market | 25,000 Shares held | 8/25/2021 | View profile |
| Smith Sean Michael Principal Accounting Officer | ▼ Sell | Open Market | 21,637 Shares held | 8/11/2023 | View profile |
| Jordan Julie Chief Medical Officer | ▼ Sell | Open Market | 12,472 Shares held | 3/26/2026 | View profile |
Transaction History
| McMinn Rachel | ▲ Buy | Option Exercise | 756 | $19K | 9/22/2026 |
| Cvijic Christine Mikail | ▼ Sell | Open Market | 4,200 | $152K | 7/7/2026 |
| Cvijic Christine Mikail | ▼ Sell | Open Market | 600 | $22K | 7/6/2026 |
| Cvijic Christine Mikail | ▼ Sell | Open Market | 2,531 | $88K | 7/2/2026 |
| Cvijic Christine Mikail | ▼ Sell | Open Market | 1,530 | $54K | 7/2/2026 |
| Cvijic Christine Mikail | ▼ Sell | Open Market | 739 | $25K | 7/1/2026 |
| Cvijic Christine Mikail | ▼ Sell | Open Market | 4,800 | $156K | 5/6/2026 |
| Cvijic Christine Mikail | ▼ Sell | Open Market | 4,800 | $144K | 5/6/2026 |
| Cvijic Christine Mikail | ▼ Sell | Open Market | 2,558 | $55K | 3/26/2026 |
| McMinn Rachel | ▼ Sell | Open Market | 3,352 | $74K | 3/26/2026 |
| Jordan Julie | ▼ Sell | Open Market | 828 | $18K | 3/26/2026 |
| Cobb Stuart | ▼ Sell | Open Market | 3,991 | $81K | 3/13/2026 |
| Cobb Stuart | ▼ Sell | Open Market | 2,658 | $57K | 3/13/2026 |
| Cobb Stuart | ▼ Sell | Open Market | 148 | $3K | 3/13/2026 |
| Cvijic Christine Mikail | ▼ Sell | Open Market | 2,387 | $49K | 3/13/2026 |
| Cvijic Christine Mikail | ▼ Sell | Open Market | 1,395 | $30K | 3/13/2026 |
| Cvijic Christine Mikail | ▼ Sell | Open Market | 263 | $6K | 3/13/2026 |
| Cvijic Christine Mikail | ▼ Sell | Open Market | 4,800 | $121K | 2/27/2026 |
| Cobb Stuart | ▲ Buy | Grant | 16,500 | $0 | 2/20/2026 |
| Jordan Julie | ▲ Buy | Grant | 4,900 | $0 | 2/20/2026 |
| Cvijic Christine Mikail | ▲ Buy | Grant | 22,000 | $0 | 2/20/2026 |
| McMinn Rachel | ▲ Buy | Grant | 25,900 | $0 | 2/20/2026 |
| Cobb Stuart | ▼ Sell | Open Market | 6,797 | $103K | 5/14/2025 |
| McMinn Rachel | ▲ Buy | Grant | 23,900 | $0 | 3/26/2025 |
| Jordan Julie | ▲ Buy | Grant | 8,400 | $0 | 3/26/2025 |
| Cobb Stuart | ▲ Buy | Grant | 7,200 | $0 | 3/26/2025 |
| Cvijic Christine Mikail | ▲ Buy | Grant | 20,300 | $0 | 3/26/2025 |
| Cvijic Christine Mikail | ▼ Sell | Open Market | 4,501 | $76K | 3/13/2025 |
| Samsara BioCapital GP, LLC | ▲ Buy | Open Market | 20,748 | $517K | 11/26/2024 |
| Samsara BioCapital GP, LLC | ▲ Buy | Open Market | 10,803 | $281K | 11/26/2024 |
| Samsara BioCapital GP, LLC | ▲ Buy | Open Market | 15,219 | $407K | 11/26/2024 |
| Samsara BioCapital GP, LLC | ▲ Buy | Open Market | 2,000 | $55K | 11/26/2024 |
| McMinn Rachel | ▲ Buy | Open Market | 47,500 | $969K | 11/22/2024 |
| Cvijic Christine Mikail | ▲ Buy | Open Market | 24,000 | $491K | 11/22/2024 |
| Cobb Stuart | ▲ Buy | Grant | 20,391 | $0 | 3/13/2024 |
| Cvijic Christine Mikail | ▲ Buy | Grant | 31,903 | $0 | 3/13/2024 |
| BAKER BROS. ADVISORS LP | ▼ Sell | Other | 535,601 | — | 10/5/2023 |
| BAKER BROS. ADVISORS LP | ▼ Sell | Other | 57,049 | — | 10/5/2023 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Open Market | 7,676 | $5K | 8/17/2023 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Open Market | 93,091 | $64K | 8/17/2023 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Open Market | 5,041 | $3K | 8/17/2023 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Open Market | 61,134 | $42K | 8/17/2023 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Open Market | 366 | $250 | 8/16/2023 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Open Market | 17,124 | $12K | 8/16/2023 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Open Market | 207,676 | $141K | 8/16/2023 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Open Market | 4,434 | $3K | 8/16/2023 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Open Market | 358 | $238 | 8/15/2023 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Open Market | 4,342 | $3K | 8/15/2023 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Open Market | 1,740,581 | $1.1M | 8/15/2023 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Open Market | 143,519 | $91K | 8/15/2023 |
| Smith Sean Michael | ▼ Sell | Open Market | 1,323 | $818 | 8/11/2023 |
| Smith Sean Michael | ▲ Buy | Option Exercise | 5,000 | $0 | 8/10/2023 |
| Patel Priti | ▼ Sell | Open Market | 3,769 | $3K | 4/3/2023 |
| Patel Priti | ▲ Buy | Option Exercise | 10,000 | $0 | 3/31/2023 |
| Patel Priti | ▼ Sell | Open Market | 14,380 | $9K | 2/2/2023 |
| Smith Sean Michael | ▼ Sell | Open Market | 3,316 | $2K | 2/2/2023 |
| Smith Sean Michael | ▲ Buy | Option Exercise | 12,500 | $0 | 2/1/2023 |
| Patel Priti | ▲ Buy | Option Exercise | 35,000 | $0 | 2/1/2023 |
| Smith Sean Michael | ▲ Buy | Option Exercise | 5,000 | $0 | 8/10/2022 |
| Smith Sean Michael | ▼ Sell | Open Market | 1,655 | $2K | 8/10/2022 |
| Patel Priti | ▼ Sell | Open Market | 5,538 | $7K | 5/2/2022 |
| Patel Priti | ▲ Buy | Option Exercise | 10,000 | $0 | 4/30/2022 |
| DRACHMAN JONATHAN G | ▲ Buy | Open Market | 25,000 | $161K | 8/25/2021 |
| DRACHMAN JONATHAN G | ▲ Buy | Open Market | 25,000 | $161K | 8/25/2021 |
| DRACHMAN JONATHAN G | ▲ Buy | Open Market | 100,000 | $611K | 8/24/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Neurogene Announces Inducement Grants Under Nasdaq Rules
Neurogene disclosed that it issued inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is typically used to attract or retain key personnel without requiring shareholder approval. The announcement provides context for the stock's current position near its support level, though no new financial results or clinical data were released in this update.
Neurogene Announces Inducement Grants Under Nasdaq Rules. Neurogene disclosed that it issued inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is typically used to attract or retain key personnel without requiring shareholder approval. The announcement provides context for the stock's current position near its support level, though no new financial results or clinical data were released in this update.